|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
Forty-nine cases (41 patients) with CD8+ CTCLs/LPDs were examined, including CD8+ mycosis fungoides (MF) (n = 14), aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (AETCL) (n = 8), subcutaneous panniculitis-like T-cell lymphoma (SPTCL) (n = 7), CD30+ LPDs (n = 6), primary cutaneous γδ T-cell lymphoma (GDTCL) (n = 6), and others (n = 8).
|
31355940 |
2020 |
|
Mycosis Fungoides
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These two cases had more prominent epidermotropism, less epidermal ulceration, and less vascular damage relative to cases with CD30 expression and therefore resembled mycosis fungoides and type B LyP.
|
30520526 |
2019 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
There is evidence that MF and pc CD30 LPD may coexist and share T-cell clonality, suggesting a common origin.
|
30946099 |
2019 |
|
Mycosis Fungoides
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The MF cohort had an average CD30 expression of 4%, while the MF-LCT cohort had an average CD30 expression of 22% (P < 0.05).
|
30328119 |
2019 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
At present, brentuximab vedotin, an antibody-drug conjugate composed of an anti-cluster of differentiation (CD)-30 antibody covalently linked to monomethyl auristatin E, is approved for the treatment of CD30+ lymphoproliferative disorders [lymphomatoid papulosis (LyP) and primary cutaneous-anaplastic large-cell lymphoma (pc-ALCL)] as well as transformed CD30+ mycosis fungoides (MF).
|
30430444 |
2019 |
|
Mycosis Fungoides
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This case highlights the point that rigid inclusion criteria for MF trials without use of more sensitive techniques to confirm lack of CD30 expression may inappropriate.
|
30659762 |
2019 |
|
Mycosis Fungoides
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The most frequent CTCL subtypes, in decreasing order of prevalence, were mycosis fungoides (MF), including its variants (75.7%); CD30+ primary cutaneous lymphoproliferative disorders (7.2%); and Sézary syndrome (SS) (3.1%).
|
30294921 |
2019 |
|
Mycosis Fungoides
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, received extended approval by the US FDA in 2017 to include primary cutaneous anaplastic large-cell lymphoma and CD30-expressing MF.
|
30943788 |
2019 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
Four of these patients subsequently developed MF; (3) Lymphomatoid papulosis (waxing and waning lesions and positivity for CD30) (n=10; M:F=4:6; median age, 41 y; range, 16 to 83 y); (4) MF (clinical features typical of MF) (n=11; M:F=6:5; median age, 17 y; range, 8 to 85 y).
|
29851705 |
2018 |
|
Mycosis Fungoides
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We report a patient with MF tumor stage with large-cell transformation and low CD30 expression with good response to brentuximab vedotin and unusual extensive xanthomatous changes in the follow-up biopsy.
|
29806104 |
2018 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
Within this nosologic umbrella are nodular and diffuse infiltrates resembling low grade T and B cell lymphoma consistent with lymphocytoma cutis, drug associated reversible T cell dyscrasias which draw a strong morphologic and phenotypic parallel with mycosis fungoides and the various pre-lymphomatous T cell dyscrasias, and angiocentric CD30 positive infiltrates mirroring lymphomatoid papulosis.
|
29361381 |
2018 |
|
Mycosis Fungoides
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In order of frequency, diagnoses were: mycosis fungoides (40.5%), peripheral T-cell lymphoma not otherwise specified (22.95%), adult T-cell lymphoma/leukemia (18.9%), CD30+ lymphoproliferative disorders (6.8%), hydroa vacciniforme-like lymphoma (5.4%), extranodal NK/T-cell lymphoma (4.1%) and Sézary syndrome (1.4%).
|
29166501 |
2018 |
|
Mycosis Fungoides
|
0.100 |
GeneticVariation
|
group |
BEFREE |
T-cell lymphoma represented 78.7% of all cases, the majority being early mycosis fungoides (MF) (64%; median age: 66 years), followed by lymphomatoid papulosis (LyP) (19%; median: age 48 years), and others (median age: 72 years), including eight cases of anaplastic large CD30+ T-cell lymphoma, four CD4+ small-medium pleomorphic T-cell lymphoproliferative disorder, four Sézary syndrome, one subcutaneous panniculitis-like T-cell lymphoma, one extranodal NK/T-cell lymphoma nasal-type, and one angioimmunoblastic T-cell lymphoma.
|
29171395 |
2018 |
|
Mycosis Fungoides
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumour cells of t-MF expressed CD30 and MUM1 in 82% and 100% cases, respectively.
|
30348505 |
2018 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin.
|
28805086 |
2017 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ LPDs comprise approximately 25%-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T-cell neoplasm of the skin behind mycosis fungoides.
|
28342276 |
2017 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
In this international, open-label, randomised, phase 3, multicentre trial, we enrolled adult patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma who had been previously treated.
|
28600132 |
2017 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
|
28497585 |
2017 |
|
Mycosis Fungoides
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PD-1 staining was observed amidst many neoplastic T-cells in 6/9(66.7%) and 62/103 (60.2%) cases of SS and MF respectively, while only 6/42 (14.3%) cases of CLD and 0/20 (0%) cases of CD30+ LPD (P<0.001).
|
28648940 |
2017 |
|
Mycosis Fungoides
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL), followed by CD30+ lymphoproliferative disorders, including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL).
|
26266670 |
2016 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
Cutaneous T-cell lymphomas (CTCL) are skin malignancies including mycosis fungoides (MF) and CD30(+) lymphoproliferative disorders (LPD).
|
27345620 |
2016 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
After bone marrow transplantation, the transformed CD30 cutaneous T-cell lymphoma recurred as a transformed CD30 plaque MF.
|
25548993 |
2015 |
|
Mycosis Fungoides
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The clinical and pathologic characteristics of the CD30 TLPDs were similar to those of their extravascular counterparts, including extralymphatic dermal involvement in a subset, DUSP22-IRF4 translocations in half of tested ALK ALCLs, and associated mycosis fungoides in 1; most were skin-limited at baseline and remained so at relapse.
|
24805854 |
2014 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
To examine this potential association, biopsies from patients with a history of MF or primary cutaneous CD30-T-LPD and lymph node biopsies reported as either CD30-positive T-cell lymphoma (TCL) with Hodgkin-like cells or cHL were retrieved from the authors' institution.
|
22367293 |
2012 |
|
Mycosis Fungoides
|
0.100 |
Biomarker
|
group |
BEFREE |
We conducted immunohistochemical analysis of 36 MF and 36 CD30(+)d skin biopsy specimens with antibodies against Fas, Fas ligand, FLICE-like inhibitory protein, Fas-associated death domain, and total and cleaved caspases 8 and 3.
|
22884443 |
2012 |